Acorda Therapeutics Inc. is reducing its workforce by 25% in a restructuring to focus its resources on the launch of its Parkinson's disease treatment Inbrija.
The Ardsley, N.Y.-based drugmaker said it expects the workforce reduction to be completed in the first quarter of 2020.
Inbrija is a formulation of levodopa, one of the main drugs used to treat certain symptoms of Parkinson's disease. The therapy is used for patients experiencing so-called off periods when the effects of an existing medication start to wear off in between doses or the symptoms of Parkinson's reemerge.
The drug is approved by the U.S. Food and Drug Administration and the European Commission.